"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
| Descriptor ID |
D001549
|
| MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 0 | 2 |
| 1998 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 10 | 10 |
| 2002 | 0 | 34 | 34 |
| 2003 | 1 | 47 | 48 |
| 2004 | 1 | 48 | 49 |
| 2005 | 0 | 33 | 33 |
| 2006 | 3 | 50 | 53 |
| 2007 | 3 | 72 | 75 |
| 2008 | 1 | 61 | 62 |
| 2009 | 3 | 63 | 66 |
| 2010 | 4 | 65 | 69 |
| 2011 | 12 | 46 | 58 |
| 2012 | 12 | 43 | 55 |
| 2013 | 25 | 15 | 40 |
| 2014 | 15 | 18 | 33 |
| 2015 | 7 | 5 | 12 |
| 2016 | 7 | 6 | 13 |
| 2017 | 10 | 11 | 21 |
| 2018 | 5 | 8 | 13 |
| 2019 | 5 | 15 | 20 |
| 2020 | 10 | 6 | 16 |
| 2021 | 8 | 13 | 21 |
| 2022 | 1 | 10 | 11 |
| 2023 | 1 | 3 | 4 |
| 2024 | 7 | 5 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10).
-
Momelotinib for the treatment of myelofibrosis. Blood. 2024 08 15; 144(7):708-713.
-
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM. Future Oncol. 2024; 20(30):2259-2270.
-
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Res. 2024 Jul 22; 52(13):7740-7760.
-
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Clin Adv Hematol Oncol. 2024 Jul-Aug; 22 Suppl 5(6):1-20.
-
Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2024 Aug; 103(8):3083-3093.
-
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
-
Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor. Commun Biol. 2024 04 04; 7(1):411.
-
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1111-1120.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.